Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jan 18, 2022 1:38pm
130 Views
Post# 34329408

RE:RE:RE:RE:La Presse article

RE:RE:RE:RE:La Presse article
EbbFlow88 wrote: I was interested in that Q&A section also.

I understand it that it's more of a disappointment as in the following paragraph she continues that the stock was higher when they had just cash and nothing else to show. In the last year, ending septebmer 30th they have 240M in revenues and 40M in cash flow, increasing results in last three quarters and the Exelon acquisition and the market is not reflecting it.


Yes - but she knows better than anyone how to wait for the market to swing in her favour.
She has never tried to force the market to love you.
Waiting is hard but if you have thick skin - no problem - the market alwasy comes around if there's real growth.

And - Samira has thick skin.  Ever seen her handle Goodman?  She's good.
<< Previous
Bullboard Posts
Next >>